Recent tensions between the United States and China have extended into the biotech and pharmaceutical sectors, sparking bipartisan calls for increased regulatory scrutiny. At the heart of the matter: clinical trials conducted by U.S. pharmaceutical companies in collaboration with Chinese
AN2 Therapeutics, a prominent biopharmaceutical company, has announced a major restructuring of its operations following an unexpected clinical trial outcome. This decision marks a significant strategic pivot from their previous research initiatives and has substantial implications for the
The latest findings from Kiromic BioPharma’s phase 1/2 clinical trial spotlight the promising potential of its investigational therapy, Deltacel (KB-GDT-01), an allogeneic gamma delta T-cell (GDT) therapy. This novel therapy is being evaluated for patients with non-small cell lung cancer (NSCLC) w
A groundbreaking advancement in tumor immunotherapy is unfolding with the approval of a new mRNA vaccine for Epstein-Barr virus (EBV) positive tumors by China's National Medical Products Administration (NMPA) for Phase-I clinical trials. Developed independently by WestGene Biopharma Co., Ltd.,
Pfizer Inc. has unveiled a significant advancement in their ongoing Phase 3 MONeT trial, specifically through a substudy aiming to evaluate the efficacy and safety of its RSV vaccine, ABRYSVO, in immunocompromised adults. Historically, this vulnerable population has faced severe complications from
The pharmaceutical industry is undergoing a significant transformation driven by the integration of data analytics, reshaping various aspects such as drug discovery, clinical trials, supply chain management, and commercial strategies. This change is not just a trend but a necessity as the industry
